CYT3 — Clenbuterol, Liothyronine and Yohimbine Fat Loss Stack by Dragon Pharma
CYT3 is Dragon Pharma's advanced three-component fat loss formulation combining Clenbuterol, Liothyronine (T3) and Yohimbine in a single 37mcg tablet — three compounds that target fat loss through three entirely different biological mechanisms simultaneously. Supplied in a 100-tablet pack, CYT3 is designed for experienced users who have already used each component individually and understand the demands of each.
Also searched as: CYT3 fat burner, CY3 Dragon Pharma, Clen T3 Yohimbine stack, CYT3 37mcg tabs.
Why This Specific Combination — Three Pathways Simultaneously
The rationale for combining Clenbuterol, T3 and Yohimbine is mechanistic — each compound targets a different fat loss pathway that the others cannot access:
| Compound | Receptor/Pathway | Mechanism | Unique Contribution |
|---|---|---|---|
| Clenbuterol | Beta-2 adrenergic receptors (β2-AR) | Thermogenesis via mitochondrial uncoupling; lipolysis via HSL activation; anti-catabolic via mTOR | Directly stimulates fat cell breakdown; also preserves lean mass during caloric deficit |
| Liothyronine (T3) | Thyroid hormone receptors (TRα, TRβ) | Increases BMR by upregulating metabolic gene expression across all tissues; accelerates nutrient turnover | Systemic metabolic acceleration that Clenbuterol and Yohimbine cannot replicate — the most powerful BMR elevator of the three |
| Yohimbine | Alpha-2 adrenergic receptors (α2-AR) | Blocks α2-AR — the receptor that inhibits fat release from stubborn fat areas (lower abdomen, hips, thighs) | The only component that specifically targets alpha-2 receptor-dense "stubborn fat" depots |
The Clenbuterol + Yohimbine Synergy — Why Alpha and Beta Matter Together
This synergy is rarely explained in competitor content and represents a genuine information gap:
- Fat cells contain both beta-2 adrenergic receptors (β2-AR) which promote lipolysis when activated, and alpha-2 adrenergic receptors (α2-AR) which inhibit lipolysis when activated
- Clenbuterol activates β2-AR — pushing the fat cell toward releasing stored fat. However, in alpha-2 receptor-dense "stubborn fat" areas (typically lower abdomen in men, hips and thighs in women), the inhibitory α2-AR signal partially counteracts the β2-AR stimulation from Clenbuterol
- Yohimbine blocks α2-AR — removing this inhibitory brake. When Yohimbine blocks α2-AR simultaneously with Clenbuterol activating β2-AR, there is no competing inhibitory signal in stubborn fat depots
- The combination produces a more complete lipolytic signal in stubborn areas than either compound alone — Clenbuterol accelerates, Yohimbine removes the brake
T3's Role — Why It Is the Most Powerful but Most Demanding Component
Liothyronine (T3) is synthetic triiodothyronine — the active thyroid hormone. Its inclusion in CYT3 is the element most requiring caution:
- T3 increases basal metabolic rate more significantly than either Clenbuterol or Yohimbine — by upregulating metabolic gene expression directly in cells across all tissues simultaneously
- Unlike Clenbuterol which downregulates its receptors over 2 weeks, T3's metabolic effects do not display the same receptor downregulation — making it effective throughout a cycle
- However, T3 is not selective for fat tissue — it accelerates catabolism of all energy substrates including muscle protein. Without adequate AAS support or high protein intake, T3 at high doses can cause significant lean mass loss alongside fat loss
- T3 also suppresses natural thyroid hormone production (TSH/T4) during use — natural thyroid function takes time to recover after stopping, requiring gradual tapering rather than abrupt cessation
Fixed-Ratio Blend vs Standalone — The Advanced User Consideration
CYT3's fixed-ratio tablet format is its key practical advantage and limitation simultaneously:
- Advantage: Convenience — one tablet delivers all three compounds without managing three separate products, dosing schedules and logistics
- Limitation: The ratio of Clenbuterol to T3 to Yohimbine is fixed at the manufacturer's chosen proportion. Advanced users who want to run Clenbuterol at a higher dose relative to T3, or who want to cycle Clenbuterol on/off (2 weeks on/off) independently from T3, cannot do so with a fixed-ratio tablet
- For users new to all three compounds or wanting a straightforward starting point, CYT3's pre-combined format is the most accessible option. Advanced users who have dialled in individual doses of each compound may prefer standalone products: Clenbuterol 40mcg, T3, standalone Yohimbine
Effects and Benefits
- Three-pathway fat loss — thermogenic (Clenbuterol), metabolic acceleration (T3) and stubborn fat α2-AR blockade (Yohimbine) simultaneously
- Anti-catabolic lean mass preservation from Clenbuterol's beta-2 muscle receptor activity
- Enhanced energy and training capacity from the combined sympathomimetic stimulation
- Convenient single-tablet format covering all three compounds
- No suppression of natural testosterone — does not affect the HPG axis (T3 affects thyroid axis only)
Side Effects
CYT3's side effect profile is the sum of all three components:
- From Clenbuterol: tremors, elevated heart rate, insomnia, muscle cramps (taurine depletion) — see Clenbuterol 40mcg page for full detail
- From T3: increased sweating and heat production, potential muscle catabolism at higher doses, suppression of natural thyroid function requiring gradual taper on discontinuation
- From Yohimbine: anxiety, elevated heart rate, blood pressure increases — Yohimbine can exacerbate anxiety and is contraindicated in individuals with anxiety disorders or cardiovascular conditions
- All three compounds are sympathomimetic or stimulant in nature — cardiovascular load is additive; those with cardiac conditions should avoid this combination
Dosage and Administration
| Week | Daily Dose | Tablets | Notes |
|---|---|---|---|
| Week 1 | Start low | ½–1 tab/day | Assess tolerance to all three components simultaneously |
| Week 2–4 | Standard dose | 1–2 tabs/day | Morning dosing preferred — all three are stimulatory |
| Discontinuation | Taper down | Reduce gradually | T3 component requires gradual taper — do not stop abruptly |
Morning dosing is essential — all three compounds are stimulatory and will significantly disrupt sleep if taken in the afternoon or evening. Unlike standalone Clenbuterol where 2-week on/off cycling is standard, the T3 component of CYT3 requires gradual tapering rather than abrupt cessation. Taurine supplementation (3-5g/day) remains recommended to manage Clenbuterol-driven muscle cramps within the blend.
CYT3 in a Fat Loss Protocol
- Testosterone Propionate or Enantat 250 as an AAS base — particularly important with CYT3 given T3's catabolic potential; testosterone base protects lean mass during aggressive fat loss
- Anavar as an additional lean mass-preserving oral alongside CYT3
"CYT3 was formulated to combine three fat loss mechanisms in a single tablet — each compound targeting a pathway the others cannot reach. It's the most concentrated fat loss stack in our oral range."
Storage and Handling
Store CYT3 at room temperature, away from direct sunlight and moisture. Keep the original packaging sealed until use to maintain tablet potency over the product's shelf life.
